Renal and hemodynamic effects of dopamine in infants following cardiac surgery

K M Outwater1, S T Treves, P Lang

  • 1Department of Pediatrics, Children's Hospital, Boston, MA.

Insights

High-dose dopamine in infants undergoing cardiac surgery improves cardiac index without adverse renal effects. Infants require higher dopamine doses than adults for similar hemodynamic benefits, demonstrating safety in postoperative care.

Area of Science:

  • Pediatric Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Congenital cardiac defects often require surgical repair in infants.
  • Postoperative hemodynamic management is critical for infant recovery.
  • Dopamine is a common inotrope used in pediatric critical care.

Purpose of the Study:

  • To evaluate the renal and hemodynamic effects of varying dopamine infusion rates in infants.
  • To determine the dose-response relationship of dopamine in this population.
  • To assess the safety of higher dopamine doses in infants post-cardiac surgery.

Main Methods:

  • Six infants undergoing congenital cardiac defect repair were studied.
  • Dopamine was infused at 5, 10, and 15 micrograms/kg/min.
  • Hemodynamic parameters (CI, RAP, LAP, PAP, SVR, PVR, HR) and renal function (GFR, urine output) were monitored.

Main Results:

  • Cardiac index (CI) significantly increased at 15 micrograms/kg/min dopamine.
  • Glomerular filtration rate (GFR) and urine output increased at lower doses (5-10 micrograms/kg/min) but normalized at 15 micrograms/kg/min.
  • No significant changes in pressures (RAP, LAP, systemic, pulmonary) or resistance (SVR, PVR) were observed; heart rate increased slightly at the highest dose.

Conclusions:

  • Infants require higher dopamine doses (15 micrograms/kg/min) for significant hemodynamic effects compared to adults.
  • These higher doses can be safely administered without compromising renal function.
  • Dopamine is effective for improving cardiac output in infants post-cardiac surgery.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...